KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to $49.3 million.

  • Biomarin Pharmaceutical's Share-based Compensation rose 13.28% to $49.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.4 million, marking a year-over-year decrease of 8.85%. This contributed to the annual value of $201.6 million for FY2024, which is 2.67% down from last year.
  • Biomarin Pharmaceutical's Share-based Compensation amounted to $49.3 million in Q3 2025, which was up 3.65% from $47.5 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Share-based Compensation high stood at $58.2 million for Q1 2024, and its period low was $37.7 million during Q1 2025.
  • For the 3-year period, Biomarin Pharmaceutical's Share-based Compensation averaged around $49.4 million, with its median value being $49.3 million (2025).
  • In the last 5 years, Biomarin Pharmaceutical's Share-based Compensation grew by 21.98% in 2021 and then crashed by 35.28% in 2025.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Share-based Compensation stood at $43.9 million in 2021, then rose by 6.48% to $46.7 million in 2022, then rose by 17.38% to $54.9 million in 2023, then fell by 5.35% to $51.9 million in 2024, then increased by 13.28% to $49.3 million in 2025.
  • Its Share-based Compensation was $49.3 million in Q3 2025, compared to $47.5 million in Q2 2025 and $37.7 million in Q1 2025.